Sustainability | April 17, 2025
Aarti Pharmalabs achieves SBTi approval of GHG emission reduction targets
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
The net-zero target approval complements the company's near-term emission reduction targets
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock
Subscribe To Our Newsletter & Stay Updated
